Is Prostate-Specific Antigen Screening Still Worth It?

The Trial Evidence Is Modest, Not Neutral

Older debates often treated prostate-specific antigen (PSA) screening as either clearly lifesaving or clearly harmful. Randomized trials show a narrower answer. Organized, repeated PSA screening in the right age range can reduce deaths from prostate cancer, but the absolute benefit is small and an overall survival benefit has not been consistently shown.

In the European Randomized Study of Screening for Prostate Cancer, a randomized trial, the core analysis focused on 162,389 men aged 55 to 69 at 16 years. PSA screening reduced prostate cancer mortality. The rate ratio was 0.80, where 1.0 would mean no difference. The absolute risk difference was 0.18%, meaning 570 men had to be invited to screening to prevent one prostate cancer death.

A later 23-year final analysis reported a smaller relative effect but a slightly larger absolute benefit over time. In the core age group of 162,236 men, the prostate cancer mortality rate ratio was 0.87, with an absolute risk reduction of 0.22%. The number needed to invite to screening to prevent one prostate cancer death was 456.

The U.S. Prostate, Lung, Colorectal, and Ovarian trial, another randomized trial, found no prostate cancer mortality reduction at a median 15 years, with a rate ratio of 1.04. That result is hard to interpret as a clean no-screening comparison because 86% of men in the control group had at least one PSA test during the trial.

The Stage Shift Is The Warning Signal

One reason the screening debate has reopened is the rise in more advanced disease after PSA screening recommendations became more restrictive. U.S. registry studies after the 2008 and 2012 U.S. Preventive Services Task Force changes found fewer localized diagnoses and more metastatic or distant-stage diagnoses. The task force later revised its recommendation in 2018 to shared decision-making for men aged 55 to 69.

In Surveillance, Epidemiology, and End Results (SEER) 18 registry data, distant metastatic prostate cancer in men aged 45 to 74 was stable from 2004 to 2010, then rose 5.3% per year through 2018.

These are observational population trends, so they cannot prove that less screening caused the full increase. Better staging imaging, including prostate-specific membrane antigen positron emission tomography (PSMA-PET), and delayed diagnosis may both contribute. The pattern is still consistent with randomized evidence. European trial analyses have reported lower metastatic disease with PSA screening, with estimates around a rate ratio of 0.65 to 0.67.

A PSA Result Is A Signal, Not A Verdict

Prostate-specific antigen (PSA) is a protein produced by the prostate and measured in blood. An elevated value is not a cancer diagnosis. The same value can mean different things depending on age, prior PSA values, prostate size, medications, and whether the result is persistent.

PSA density is one useful refinement. It divides PSA by prostate volume, often measured on magnetic resonance imaging (MRI), so a larger benign prostate is not interpreted the same way as a smaller prostate with the same PSA level. Evidence from diagnostic studies supports using PSA density as part of a broader risk assessment, not as a stand-alone rule.

PSA velocity means the rate of PSA change over time. It is less reliable as a stand-alone biopsy trigger. The American Urological Association and Society of Urologic Oncology guideline recommends against using PSA velocity alone to decide on biopsy or secondary biomarkers. Serial PSA still matters because it can help confirm whether a signal is persistent and interpretable.

Magnetic Resonance Imaging Changed The Next Step

Modern evaluation often puts magnetic resonance imaging (MRI) between an abnormal prostate-specific antigen (PSA) result and biopsy. In the 2025 PRIME diagnostic trial of 490 biopsy-naive men, contrast-free biparametric MRI was noninferior to multiparametric MRI for detecting clinically significant cancer, defined as Grade Group 2 or higher. Biparametric MRI found clinically significant cancer in 143 of 490 men, compared with 145 of 490 using multiparametric MRI.

MRI also changes how many low-grade cancers are found. In the PRECISION randomized trial of 500 biopsy-naive men, an MRI pathway detected a similar proportion of clinically significant cancers compared with systematic transrectal ultrasound biopsy, 25% versus 23%. It detected fewer clinically insignificant cancers, 14% versus 25%, and avoided biopsy in 28% of men by not biopsying those with a negative MRI.

If biopsy is needed, route matters. In the multicenter PREVENT randomized trial, 875 patients were randomized and 742 underwent biopsy. Grade 2 or higher infections occurred in 0 men in the transperineal group versus 6 men, or 1.6%, in the transrectal group. High-grade cancer detection was similar, 55% versus 52%, so the main proven advantage in that trial was infection reduction.

Detection Does Not Always Mean Treatment

The harm of prostate-specific antigen (PSA) screening is not only the blood test. It is the cascade: biopsy, a cancer label, and treatment of tumors that may never have caused symptoms. Pathology grades prostate cancer from Grade Group 1 to 5. Grade Group 1, and some favorable Grade Group 2 cancers, may be appropriate for active surveillance rather than immediate surgery or radiation.

Active surveillance means close monitoring instead of immediate treatment. It can include repeated PSA testing, symptom tracking, follow-up imaging, and repeat biopsy if warning signs arise. This approach is meant to reduce overtreatment while still watching for disease that becomes more concerning.

The ProtecT randomized trial followed 1,643 men with localized prostate cancer for a median of 15 years. Prostate cancer-specific mortality was low across active monitoring, surgery, and radiotherapy: 3.1%, 2.2%, and 2.9%. Metastases were higher with active monitoring, 9.4%, than with prostatectomy, 4.7%, or radiotherapy, 5.0%.

ProtecT also used an active monitoring protocol that was less intensive than many modern active surveillance programs, with no routine repeat biopsy or MRI. Finding a low-risk cancer should start a risk discussion, not automatically a treatment plan.

Finasteride Can Hide The Signal

Finasteride and dutasteride are 5-alpha reductase inhibitors, drugs that shrink prostate tissue and suppress prostate-specific antigen (PSA). The U.S. Food and Drug Administration label for finasteride states that PSA falls by about 50% within 6 months. After at least 6 months of therapy, an isolated PSA value should be doubled for comparison with normal ranges in untreated men. Any confirmed rise from the lowest PSA value on therapy should be evaluated.

This adjustment is not a minor technicality. In an observational Veterans Affairs cohort of 80,875 men with prostate cancer, men taking a 5-alpha reductase inhibitor had a longer time from first adjusted elevated PSA to biopsy, 3.60 versus 1.40 years. They also had higher adjusted PSA at biopsy, 13.5 versus 6.4 ng/mL, and more metastatic disease at diagnosis, 6.7% versus 2.9%.

Because that Veterans Affairs study was observational, it cannot prove that 5-alpha reductase inhibitors caused worse outcomes. Men using these drugs may differ in age, prostate size, and patterns of care. The practical point is clearer: if you take finasteride or dutasteride, PSA must be interpreted with that medication effect in mind.

How To Use This Clinically

Current U.S. Preventive Services Task Force guidance treats prostate-specific antigen (PSA) screening for men aged 55 to 69 as an individual decision and recommends against routine screening at age 70 or older. That position fits the evidence: PSA screening has a real but modest disease-specific benefit, and the decision depends on your risk, life expectancy, medication history, and willingness to follow an abnormal result.

If you choose screening, the practical standard should be higher than simply checking PSA once every few years. A better pathway asks whether the result was repeated, whether prior values show a meaningful pattern, whether prostate volume makes PSA density interpretable, whether magnetic resonance imaging (MRI) should come before biopsy, whether transperineal biopsy is available, and whether active surveillance is appropriate if low-risk cancer is found.

PSA is something you can measure and track over time. Its value comes from clinician-reviewed interpretation, not the number alone.